Literature DB >> 23352590

The influence of 5-lipoxygenase on Alzheimer's disease-related tau pathology: in vivo and in vitro evidence.

Jin Chu1, Jian-Guo Li, Carolina Ceballos-Diaz, Todd Golde, Domenico Praticò.   

Abstract

BACKGROUND: Intracellular deposition of tau protein is a hallmark lesion of Alzheimer's disease. Although it is known this event is secondary to excessive tau phosphorylation, the mechanisms involved remain unknown. We previously reported that the enzyme 5-Lipoxygenase (5LO) acts as a modulator of Aβ peptides formation in vivo, and here we investigate its influence on tau protein.
METHODS: Tg2576 mice overexpressing neuronal 5LO were generated and its contribution to endogenous tau levels and metabolism investigated.
RESULTS: Although no differences were noted in the levels of total tau for both groups, compared with controls, Tg2576 mice overexpressing 5LO had a significant increase in the phosphorylation state of tau at S396 and S396/S404, as recognized by the antibodies PHF-13 and PHF-1, respectively. By contrast, no phosphorylation changes were observed in other tau epitopes. This increase was associated with a significant elevation in cyclin dependent kinase-5 but not other kinases that have been involved in tau phosphorylation. Additionally, mice overexpressing 5LO had biochemical evidence of altered synaptic integrity because they manifested a reduction in PSD-95, synaptophysin and MAP2.
CONCLUSIONS: This study demonstrates a new role for 5LO in regulating endogenous tau metabolism in the central nervous system and supports the hypothesis that its pharmacologic inhibition could be beneficial for Alzheimer's disease-related tau neuropathology.
Copyright © 2013 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  5-Lipoxygenase; Alzheimer’s disease; amyloid beta; cyclin dependent kinase-5; tau protein; transgenic mouse model

Mesh:

Substances:

Year:  2013        PMID: 23352590      PMCID: PMC3726558          DOI: 10.1016/j.biopsych.2012.12.012

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  31 in total

1.  5-Lipoxygenase (5-LOX) promoter polymorphism in patients with early-onset and late-onset Alzheimer's disease.

Authors:  T Qu; R Manev; H Manev
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2001       Impact factor: 2.198

2.  Glycogen synthase kinase-3beta is complexed with tau protein in brain microtubules.

Authors:  Wei Sun; Hamid Y Qureshi; Patrick W Cafferty; Kazuya Sobue; Alka Agarwal-Mawal; Katherine D Neufield; Hemant K Paudel
Journal:  J Biol Chem       Date:  2002-01-25       Impact factor: 5.157

Review 3.  Cdk5: one of the links between senile plaques and neurofibrillary tangles?

Authors:  Ming-Sum Lee; Li-Huei Tsai
Journal:  J Alzheimers Dis       Date:  2003-04       Impact factor: 4.472

4.  Activation of the JNK/p38 pathway occurs in diseases characterized by tau protein pathology and is related to tau phosphorylation but not to apoptosis.

Authors:  C Atzori; B Ghetti; R Piva; A N Srinivasan; P Zolo; M B Delisle; S S Mirra; A Migheli
Journal:  J Neuropathol Exp Neurol       Date:  2001-12       Impact factor: 3.685

5.  Activation of c-Jun N-terminal kinase and p38 in an Alzheimer's disease model is associated with amyloid deposition.

Authors:  Mary J Savage; Yin-Guo Lin; John R Ciallella; Dorothy G Flood; Richard W Scott
Journal:  J Neurosci       Date:  2002-05-01       Impact factor: 6.167

6.  5-Lipoxygenase gene transfer worsens memory, amyloid, and tau brain pathologies in a mouse model of Alzheimer disease.

Authors:  Jin Chu; Phillip F Giannopoulos; Carolina Ceballos-Diaz; Todd E Golde; Domenico Praticò
Journal:  Ann Neurol       Date:  2012-09       Impact factor: 10.422

7.  Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms.

Authors:  Cathy Andorfer; Yvonne Kress; Marisol Espinoza; Rohan de Silva; Kerry L Tucker; Yves-Alain Barde; Karen Duff; Peter Davies
Journal:  J Neurochem       Date:  2003-08       Impact factor: 5.372

8.  Overactivation of glycogen synthase kinase-3 by inhibition of phosphoinositol-3 kinase and protein kinase C leads to hyperphosphorylation of tau and impairment of spatial memory.

Authors:  Shi Jie Liu; Ai Hong Zhang; Hong Lian Li; Qun Wang; Heng Mei Deng; William J Netzer; Huaxi Xu; Jian Zhi Wang
Journal:  J Neurochem       Date:  2003-12       Impact factor: 5.372

Review 9.  Tau phosphorylation, tangles, and neurodegeneration: the chicken or the egg?

Authors:  Daniel H Geschwind
Journal:  Neuron       Date:  2003-10-30       Impact factor: 17.173

10.  p39 activates cdk5 in neurons, and is associated with the actin cytoskeleton.

Authors:  S Humbert; R Dhavan; L Tsai
Journal:  J Cell Sci       Date:  2000-03       Impact factor: 5.285

View more
  10 in total

1.  1-(7-Chloroquinolin-4-yl)-N-(4-Methoxybenzyl)-5-Methyl-1H-1,2, 3-Triazole-4- carboxamide Reduces Aβ Formation and Tau Phosphorylation in Cellular Models of Alzheimer's Disease.

Authors:  Mariana G Fronza; Manoela Sacramento; Diego Alves; Domenico Praticò; Lucielli Savegnago
Journal:  Neurochem Res       Date:  2022-02-15       Impact factor: 3.996

2.  Gamma secretase-activating protein is a substrate for caspase-3: implications for Alzheimer's disease.

Authors:  Jin Chu; Jian-Guo Li; Yash B Joshi; Phillip F Giannopoulos; Nicholas E Hoffman; Muniswamy Madesh; Domenico Praticò
Journal:  Biol Psychiatry       Date:  2014-06-16       Impact factor: 13.382

Review 3.  Novel lipid signaling pathways in Alzheimer's disease pathogenesis.

Authors:  Phillip F Giannopoulos; Yash B Joshi; Domenico Praticò
Journal:  Biochem Pharmacol       Date:  2013-11-21       Impact factor: 5.858

4.  Zileuton restores memory impairments and reverses amyloid and tau pathology in aged Alzheimer's disease mice.

Authors:  Antonio Di Meco; Elisabetta Lauretti; Alana N Vagnozzi; Domenico Praticò
Journal:  Neurobiol Aging       Date:  2014-05-27       Impact factor: 4.673

Review 5.  The 5-lipoxygenase pathway: oxidative and inflammatory contributions to the Alzheimer's disease phenotype.

Authors:  Yash B Joshi; Domenico Praticò
Journal:  Front Cell Neurosci       Date:  2015-01-14       Impact factor: 5.505

Review 6.  Intersection of pathological tau and microglia at the synapse.

Authors:  Thomas Vogels; Adriana-Natalia Murgoci; Tomáš Hromádka
Journal:  Acta Neuropathol Commun       Date:  2019-07-05       Impact factor: 7.801

Review 7.  Fair-Weather Friends: Evidence of Lipoxin Dysregulation in Neurodegeneration.

Authors:  Changmo Kim; Izhar Livne-Bar; Karsten Gronert; Jeremy M Sivak
Journal:  Mol Nutr Food Res       Date:  2020-01-07       Impact factor: 5.914

8.  Targeting the ensemble of heterogeneous tau oligomers in cells: A novel small molecule screening platform for tauopathies.

Authors:  Chih Hung Lo; Colin Kin-Wye Lim; Zhipeng Ding; Sanjula P Wickramasinghe; Anthony R Braun; Karen H Ashe; Elizabeth Rhoades; David D Thomas; Jonathan N Sachs
Journal:  Alzheimers Dement       Date:  2019-10-22       Impact factor: 21.566

9.  The Lipoxygenases: Their Regulation and Implication in Alzheimer's Disease.

Authors:  Grzegorz A Czapski; Kinga Czubowicz; Joanna B Strosznajder; Robert P Strosznajder
Journal:  Neurochem Res       Date:  2015-12-16       Impact factor: 3.996

10.  The Leukotriene Receptor Antagonist Montelukast Attenuates Neuroinflammation and Affects Cognition in Transgenic 5xFAD Mice.

Authors:  Johanna Michael; Julia Zirknitzer; Michael Stefan Unger; Rodolphe Poupardin; Tanja Rieß; Nadine Paiement; Horst Zerbe; Birgit Hutter-Paier; Herbert Reitsamer; Ludwig Aigner
Journal:  Int J Mol Sci       Date:  2021-03-09       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.